<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05024552</url>
  </required_header>
  <id_info>
    <org_study_id>MCC-20752</org_study_id>
    <nct_id>NCT05024552</nct_id>
  </id_info>
  <brief_title>Vyxeos Plus Gilteritinib in Relapsed or Refractory, FLT3-Mutated AML</brief_title>
  <official_title>A Phase 1 Study of Vyxeos Plus Gilteritinib in Relapsed or Refractory, FLT3-Mutated Acute Myeloid Leukemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>H. Lee Moffitt Cancer Center and Research Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Jazz Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>H. Lee Moffitt Cancer Center and Research Institute</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study combines vyxeos and gilteritinib in patients with relapsed or refractory&#xD;
      FLT3-mutated acute myeloid leukemia. Vyxeos and gilteritinib will be given as induction&#xD;
      therapy. Those patients entering a complete remission or a complete remission with incomplete&#xD;
      blood count recovery will be allowed to proceed to consolidation therapy with vyxeos and&#xD;
      gilteritinib. Those patients who do not proceed to an allogeneic stem cell transplant for any&#xD;
      reason are able to enter the maintenance phase of this trial using daily gilteritinib&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 23, 2021</start_date>
  <completion_date type="Anticipated">August 2025</completion_date>
  <primary_completion_date type="Anticipated">August 2024</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum Tolerated Dose (MTD)</measure>
    <time_frame>Up to 18 months</time_frame>
    <description>Dose escalation will determine the Maximum Tolerated Dose (MTD) and Recommended Phase 2 Dose (RP2D) of Vyxeos plus Gilteritinib. The MTD is the highest dose of the combination therapy that dose not cause unacceptable side effects.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Complete Remission Rate</measure>
    <time_frame>Up to 18 months</time_frame>
    <description>Rate of complete remission (CR) and complete remission with incomplete blood count recovery (CRi). The definition of CR and CRi is based on the European LeukemiaNet 2017 Response Criteria</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Event free survival (EFS)</measure>
    <time_frame>Up to 18 months</time_frame>
    <description>Event free survival is determined as the duration of time from start of treatment to the time of cancer recurrence.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival (OS)</measure>
    <time_frame>Up to 5 years</time_frame>
    <description>Overall survival is defined as the duration of time from start of treatment to the time of death from any cause or date of last contact.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">22</enrollment>
  <condition>Acute Myeloid Leukemia With FLT3/ITD Mutation</condition>
  <arm_group>
    <arm_group_label>Dose Escalation Arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive intravenous Vyxeos on days 1, 3 and 5 and Gilteritinib will be given on days 6-19 of induction therapy. The induction and reinduction dose of Vyxeos is 44mg/m2 daunorubicin and 100mg/m2 of cytarabine with each infusion.&#xD;
Dose level 1: Vyxeos + 120 mg Gilertinib&#xD;
In the event of a dose-limiting toxicity (DLT) at the initial dose level, a dose level minus (-) 1 is permitted Dose Level -1: Vyxeos + 80 mg Gilertinib</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose Expansion Arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive intravenous Vyxeos on days 1, 3 and 5 and Gilteritinib will be given on days 6-19 of induction therapy in the dose determined in the dose escalation arm.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gilteritinib</intervention_name>
    <description>Gilteritinib is an oral inhibitor of FLT3-ITD and FLT3-TKD. Dose cohort 1 will receive 120mg daily on days 6-19 of induction and days 4-17 of re-induction and consolidation</description>
    <arm_group_label>Dose Escalation Arm</arm_group_label>
    <arm_group_label>Dose Expansion Arm</arm_group_label>
    <other_name>Xospata</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vyxeos</intervention_name>
    <description>Vyxeos is a liposomal encapsulation of cytarabine and daunorubicin. It is given as an intravenous infusion over 90 minutes on days 1, 3 and 5 of induction and days 1 and 3 of re-induction and consolidation. The induction and reinduction dose is 44mg/m2 daunorubicin and 100mg/m2 of cytarabine with each infusion. The consolidation dose is 29mg/m2 daunorubicin and 65mg/m2 of cytarabine with each dose.</description>
    <arm_group_label>Dose Escalation Arm</arm_group_label>
    <arm_group_label>Dose Expansion Arm</arm_group_label>
    <other_name>daunorubicin-cytarabine</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Provision of signed and dated informed consent form&#xD;
&#xD;
          -  Stated willingness to comply with all study procedures and availability for the&#xD;
             duration of the study&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group (ECOG) performance status ≤2&#xD;
&#xD;
          -  FLT3-ITD or FLT3-TKD mutated AML (non-M3) in 1st or greater relapse or refractory to&#xD;
             at least one prior line of AML directed therapy&#xD;
&#xD;
          -  FLT3 testing must be confirmed at the time of disease relapse&#xD;
&#xD;
          -  Adequate organ function&#xD;
&#xD;
          -  Left ventricular ejection fraction (LVEF) ≥50%&#xD;
&#xD;
          -  Prior anthracycline exposure ≤368 mg/m2 daunorubicin (or equivalent)&#xD;
&#xD;
          -  Ability to take oral medication and willingness to adhere to the medication regimen&#xD;
&#xD;
          -  For females of reproductive potential: use of highly effective contraception including&#xD;
             double barrier methods (condoms with spermicidal jelly or foam and diaphragm with&#xD;
             spermicidal jelly or foam), oral, depo provera, or injectable contraceptives,&#xD;
             intrauterine devices and tubal ligation.&#xD;
&#xD;
          -  For females of reproductive potential: negative serum or urine pregnancy test with a&#xD;
             sensitivity of at least 50mIU/mL within 10 days and again within 24 hours of beginning&#xD;
             study treatment&#xD;
&#xD;
          -  For males of reproductive potential: use of condoms&#xD;
&#xD;
          -  Breastfeeding mothers must agree to discontinue nursing&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients may not be receiving any other investigational agents&#xD;
&#xD;
          -  Patients with documented central nervous system involvement of AML&#xD;
&#xD;
          -  Any prior use of gilteritinib&#xD;
&#xD;
          -  Patients must not have evidence of GI tract abnormalities that would alter the&#xD;
             absorption of oral medications&#xD;
&#xD;
          -  Major surgery within two weeks of first dose of study drug. Patients must have&#xD;
             recovered from the effects of any surgery performed greater than two weeks prior&#xD;
&#xD;
          -  WBC count ≥50,000 at the time study treatment begins. Use of hydroxyurea to maintain&#xD;
             WBC &lt;50,000 is allowed up to the time that study treatment begins&#xD;
&#xD;
          -  Predicted inability to tolerate standard induction chemotherapy&#xD;
&#xD;
          -  Uncontrolled intercurrent illness including, but not limited to, ongoing or active&#xD;
             infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac&#xD;
             arrhythmia, or psychiatric illness/social situations that would limit compliance with&#xD;
             study requirements&#xD;
&#xD;
          -  No other malignancies in addition to AML that are currently requiring treatment with&#xD;
             the exception of: 1) basal cell or squamous cell carcinoma or the skin; 2) carcinoma&#xD;
             in situ of the cervix or breast; 3) a history of breast cancer that is currently being&#xD;
             managed with adjuvant endocrine therapy&#xD;
&#xD;
          -  Patients may not have undergone an allogeneic stem cell transplant at any time in the&#xD;
             past&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kendra L Sweet, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Moffitt Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Moffitt Cancer Center</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33612</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christine Ternival</last_name>
      <phone>813-745-2146</phone>
      <email>Christine.Ternival@moffitt.org</email>
    </contact>
    <investigator>
      <last_name>Kendra L Sweet, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Brandon Blue, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Timothy Kubal, MD, MBA</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Andrew T Kuykendall, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jeffrey E Lancet, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Eric Padron, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>David A Sallman, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.moffitt.org/research--clinical-trials/clinical-trials</url>
    <description>Moffitt Cancer Center Clinical Trials website</description>
  </link>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>August 23, 2021</study_first_submitted>
  <study_first_submitted_qc>August 23, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">August 27, 2021</study_first_posted>
  <last_update_submitted>August 23, 2021</last_update_submitted>
  <last_update_submitted_qc>August 23, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 27, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cytarabine</mesh_term>
    <mesh_term>Daunorubicin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

